[go: up one dir, main page]

WO2005113537B1 - Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions - Google Patents

Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions

Info

Publication number
WO2005113537B1
WO2005113537B1 PCT/US2005/016525 US2005016525W WO2005113537B1 WO 2005113537 B1 WO2005113537 B1 WO 2005113537B1 US 2005016525 W US2005016525 W US 2005016525W WO 2005113537 B1 WO2005113537 B1 WO 2005113537B1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
alkyl
occurrence
carbon atoms
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/016525
Other languages
French (fr)
Other versions
WO2005113537A2 (en
WO2005113537A3 (en
Filing date
Publication date
Priority claimed from US11/126,567 external-priority patent/US7550499B2/en
Priority to HR20090468T priority Critical patent/HRP20090468T1/en
Priority to DK05779448T priority patent/DK1750704T3/en
Priority to JP2007513323A priority patent/JP4795336B2/en
Priority to DE602005015577T priority patent/DE602005015577D1/en
Priority to CN2005800231306A priority patent/CN1984655B/en
Priority to EP05779448A priority patent/EP1750704B1/en
Application filed filed Critical
Priority to MXPA06013024A priority patent/MXPA06013024A/en
Priority to PL05779448T priority patent/PL1750704T3/en
Priority to AU2005245400A priority patent/AU2005245400A1/en
Priority to CNA2005800236206A priority patent/CN1984892A/en
Publication of WO2005113537A2 publication Critical patent/WO2005113537A2/en
Publication of WO2005113537A3 publication Critical patent/WO2005113537A3/en
Publication of WO2005113537B1 publication Critical patent/WO2005113537B1/en
Anticipated expiration legal-status Critical
Priority to NO20065544A priority patent/NO20065544L/en
Priority to CY20091101048T priority patent/CY1109487T1/en
Ceased legal-status Critical Current

Links

Abstract

The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.

Claims

[Received by the International Bureau on December 22, 2005 (22/12/2005); original claims 1, 10 and 11 have been amended. Other claims remain unchanged]
1. A compound of Formula (I):
Figure imgf000002_0001
(D or a stereoisomer or pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is Cδ-io aryl substituted with 0-5 R1 , or a 5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O, and S(O)p, wherein said heterocycle is substituted with 0-5 R1; ring B is phenyl or naphthyl substituted with 0-4 R?, or a 5- to 10-membered heteroaryl comprising: carbon atoms and 1-4 ring heteroatoms selected from N, NR11, S(O )p, and O, wherein said heteroaryl is substituted with 0-4 R7; ring D is substituted with 0-5 R6a and selected from:
Figure imgf000002_0002
wherein D1 is a 5- to 7-raembered carbocycle or a 5-6-membered heterocycle comprising: carbon atoms and 0-3 ring heteroatoms selected from N, NR1 ] , O, and S(O)p, and 0-2 carbonyl groups, and 0-3 double bonds;
W is O or S; X2 is -(CRJ 6Rl 7)s_5 or _(CR16R17)tC(O)(CR] ^Rl 7)r;
R1 is, independently at each occurrence, H, =0, F, Cl, Br, I5 CF3, -CF2CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)rORc, SRC, CN5 NO2, -(CRfRf)rNR12R13, -(CRfRfJr-C(O)R0, -(CRfRf)r-C02Rc, -(CRfRf)rC(O)NR12R13, -C(O)NR14(CRfRf)tN12R135 -(CRfRf)rOC(O)NR12R13, -(CRfRf)1-NR14C(O)NR12R13, -(CRfRf)rNR14C(0)Rd, -(CRfRf)rNR14C(O)ORh, -NR14(CRfRf)nC(0)Rd, -NR14CO(CRfRf)nORc, -(CH2V-CR13O=NOR0), -S(O)pNR12R13, -(CRfRf)rNR14S(O)pNR12R13, -NR14SO2CF3, -NR14S(0)pRd -S(O)2CF3, -S(O)Rd, -S(O)2Rd, -OP(O)(OEt)2, -O(CH2)2OP(O)(OEt)2; 4,4,5,5-tetramethyl-l,3,2-dioxabprolarryl, C1-8 alkyl substituted with 0-2 Ra, C2-S alkenyl substituted with 0-2 Ra, C2_8 alkynyl substituted with 0-2 Ra,
-(CRfRf)r-C3.i3 carbocycle substituted with 0-5 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-5 Rb; alternatively, two R1S on two adjacent carbon atoms are combined with the carbon atoms to which they are attached, form a 5- to 10-membered carbocycle or heterocycle comprising: carbon atoms and 0-3 additional heteroatoms selected from N, NR1 1 J O, and S(O)p, and 0-2 carbonyl groups, wherein said carbocycle or heterocycle is substituted with 0-4 Rb;
R6a is, independently at each occurrence, =0, F5 Cl, Br, I, -(CR1R1VOR0, SR0, CN, NO2, CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -(CRfRf)rNR12R13, -C(O)R0, -(CRfRf)r-C(O)OR°, -(CRfRf)1-C(O)NR12R13, -(CRfRf)rNR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, Si(Me)3, Si(Ci_4 alkyl)3, Cμ4 haloalkyl, Ci_4 haloalkyloxy-, C1-4 alkyloxy-, C1^ alkylthio-, Ci-C4 alkyl-C(O)-, Ci_4 alkyl-O-C(O)-, C]_4 allcyl-C(O)NH-, Cμ8 alkyl substituted with 0-1 Ra, C2-8 alkenyl substituted with 0-1 Ra, C2-8 alkynyl substituted with 0-1 Ra,
Figure imgf000004_0001
carbocycle substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O5 and S(O)p, wherein said heterocycle is substituted with 0-2 Re; alternatively, when two R^a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N5 NR11, O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R6a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR11, O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb;
R7 is, independently at each occurrence, H, =0, F, Cl, Br, I5 OCF3, CF3, ORC, - SRC, CN, NO2, -NR12R13, _c(0)Rc, -C(O)ORC, -C(O)NR12R13, -NR14C(0)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, C1 -8 alkyl substituted with 0-2 Ra, C2-S alkenyl substituted with 0-2 Ra, C2-S alkynyl substituted with 0-2 Ra, -(CRfRf)r-C3_io carbocycle substituted with 0-3 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR7b, O5 and S(O)p, wherein said heterocycle is substituted with 0-3 Rb; alternatively, two R7S on two adjacent carbon atoms form a 5- to 7-membered carboc3'clic or heterocyclic ring comprising: carbon atoms and 0-3 ring heteroatoms selected from O, N5 NR7b, and S(O)p, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 R7c;
R7b is H, C14 alkyl, -C(O)(Ci_4 alkyl), -C(O)phenyl, -C(O)benzyl, or benzyl; R7c is, independently at each occurrence, H, F, Cl, Br5 15 OCF3, CF3, ORC, SRc, CN, NO2, -NR12R13, -C(O)R0, -C(O)ORc, -C(O)NR12R13, -NR^C(O)Rd -S(COpNR12R13, -S(O)Rd, -S(O)2Rd, C]_4 ^i phenyl substituted with 0-3 Rb, or benzyl substituted with 0-3 Rb;
R11 is, independently at each occurrence, H, Cj-4 alkoxy, Cj.g alkyl substituted with 0-2 Ra, C2-4 alkenyl substituted with 0-1 Ra, C2-4 alkynyl substituted with 0- 1 Ra, -C(O)(C i^ alkyl), -C(O)(CH2)n(C3_6 cycloalkyl),
-C(0)(CH2)Π(C6-JO aryl), -C(O)(CH2)n(5- to 10-membered heteroaryl), -C(O)O(CL8 alkyl), -C(O)O(CH2)n(C3_6 cycloalkyl), -C(0)0(CH2)n(C6.io aryl), -C(O)O(CH2)n(5- to 10-memberedheteroaryl), -C(O)O(CH2)2_4(Ci_4 alkyl), -C(O)NH(C i_8 alkyl), -C(O)NH(CH2)n(C3-6 cycloalkyl), -C(0)NH(CH2)n(C6-io aryl), -C(O)NH(CH2)n(5- to 10-membered lieteroaryl), -S(O)2(CL8 alkyl), -S(O)2(CH2)n(C3-6 cycloalkyl), -S(O)2(CH2)n(C6_10 aryl), -S(O)2(CH2)n(5- to 10-membered heteroaryl), -(CRfRf)rC3.io carbocycle, or -(CRfRf)r-5- to 10-membered heterocycle; wherein said alkyl, cycloalkyl, phenyl, aryl, and carbocycle are substituted with 0-2 R^, and said heteroaryl and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p;
R12 is, independently at each occurrence, H5 CL6 alkyl, -C(O)(Ci_6 alkyl), -C(0)(CH2)n(C6-io aryl), -C(O)(CH2)n(5- to 10-membered heteroaryl), -C(O)O(CL4 alkyl), -C(O)OCH2(C6-I0 aryl), -(CH2)nC(O)OCH2(5- to 10-membered heteroaryl), -(CH2)nOC(0)(Ci .4 alkyl), -(CH2)nOC(0)(C6-io aryl), -(CH2)nOC(O)(5- to 10-membered heteroaryl), -(CH2)nC(O)O(CL4 alkyl), -(CH2)nC(O)O(C6-] 0 aryl), -(CH2)nC(O)O(5- to 10-membered heteroaryl), -(CH2)nC(O)NH(Ci_6 alkyl), -(CH2)aC(0)NH(C6-io aryl), -(CH2)nC(O)NH(5- to 10-membered heteroaryl), -(CH2)tOC(O)NH(Ci.6 alkyl), -(CH2)tOC(0)NH(C6_io aryl),
-(CH2)tOC(O)NH(5- to 10-membered heteroaryl), -S(O)2(CL6 alkyl), -S(0)2(CH2)n(C6-io aryl), -S(O)2(CH2)n(5- to 10-membered heteroaryl),
Figure imgf000005_0001
aryl), or -(CRfRf)n- 5- to 10-membered heteroaryl; wherein said alkyl, and aryl are substituted with 0-2 RS; and said heteroaryl is substituted with 0-2 RS and comprises: carbon atoms and 1-4 heteroatoms selected from N, NR1 !, O, and S(0)p;
R13 is, independently at each occurrence, H, Cμg alkyl, or -(CH2)n-pb-enyl; alternatively, R12 and R13, when attached to the same nitrogen, combine to form a 5- to 10-membered heterocyclic ring comprising: carbon atoms and 1-2 additional heteroatoms selected from N, NR11, O, and S(O )p;
R14 is, independently at each occurrence, H, C\.β alkyl substituted with 0-2 R14a, C2-6 alkenyl substituted with 0-2 R14a, C2-6 alkynyl substituted with 0-2 R14a, -(CH2)r-C34o carbocycle substituted with 0-3 RS, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-3 RS;
R14a is, independently at each occurrence, H, Ci_4 alkyl, ORf, Cl, F, Br, I, =0, CF3, CN5 NO2, -C(O)Rf -C(O)ORf, -C(O)NR12R13, or -S(O)pRf;
R16 is, independently at each occurrence, H, F5 Cj_6 alkyl substituted with 0-2 Ra, C2-6 alkenyl substituted with 0-2 Ra, C2-6 alkynyl substituted with. 0-2 Ra, or -(CH2)r-phenyl substituted with 0-2 Rb;
R17 is, independently at each occurrence, H, OH, Cμg alkyl, or -(CH2)n-plienyl; alternatively, R16 and R17 on the same carbon atom combine to form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR11, O, and S(O)p, 0-1 carbonyl, and 0-3 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb; alternatively, two R16 groups on adjacent atoms combine to form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 *-, O, and S(O)p, 0-1 carbonyl, and 0-3 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
Ra is, independently at each occurrence, H, =0, F, OCF3, CF3, ORC, SRC, CN5 -NRl2Rl3, _c(0)Rc, -C(O)ORC, -C(O)NR12R13, -NR14C(O)Rd, -S(O)pNR'2R13, -S(O)Rd, -S(O)2Rd, -(CH2)r-C3.io carbocycle substituted with 0-3 Re, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR/, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
Rb is, independently at each occurrence, H, =0, F, Cl, Br, I, -(CH2)rORc, SRc, CN, NO2, CF3, OCF3, -(CH2VNR12R13, -C(O)RC, ~(CH2)r-C(O)ORc, -(CH2VC(O)NR12Rl3, -NR^C(O)Rd, -S(O)pNR12R33, -S(O)Rd, -S(O)2Rd, Ci_4 haloalkyl, C1-4 haloalkyloxy-, Cj_4 alkyloxy-, C3-4 alkylthio-, C1.4 alkyl-C(O)-, CM alkyl-O-C(O)-, CM alkyl-C(O)NH-? C1-8 alkyl substituted with 0-2 Ra, C2.8 alkenyl substituted with 0-2 Ra, C2.g allcynyl substituted with 0-2 Ra, -(CH2VC3-Io carbocycle substituted with 0-3 Re, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
Rc is, independently at each occurrence, H, -0P(0)(0Et)2, Cμg alkyl substituted with 0-2 Re. C2-S alkenyl substituted with 0-2 Re, C2_8 alkynyl substituted with 0-2 Re, -(CRfRr)r-C3-8 cycloalkyl substituted with 0-2 Re, -(CRfRf)r-C6-io aryl substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N5 NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Rd is, independently at each occurrence, CF3, OH, C1.4 alkoxy, Ci_6 alkyl, -(CH2)r-C3_io carbocycle substituted with 0-2 Re, or -(CH2VS- to 10- membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O5 and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Re is, independently at each occurrence, H, =0, -(CH2)r-0Rf, F, Cl, Br, I, CN, NO2, -(CH2VNR12R13, -C(O)Rf, -(CH2VC(O)ORf -NR14C(O)Rf -(CH2VC(O)NR12R13, -SO2NR12R13, -NRWSO2NR12R13, -NR14SO2-Ci-4 alkyl, -NRWSO2CF3, -NR14SO2-phenyl, -S(O)2CF3, -S(O)p-OR\ -(CF2)rCF3, Si(Me)3, Si(Me)2(^-Bu), Si(Ci-4 alkyl)3, Cχ_8 alkyl substituted with 0-2 Rg, C2-8 alkenyl substituted with 0-2 RS5 C2_8 alkynyl substituted with 0-2 RS, -(CH2)rC3.g cycloalkyl substituted with 0-2 RS, -(CH2)rC6-io aryl substituted with 0-2 R§, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR/, O, and S(O)p, wherein said heterocycle is substituted with 0-2 RS;
Rf is, independently at each occurrence, H, Cμg alkyl, or -(CH2)n-phenyl; Rg is, independently at each occurrence, H, =0, ORf, F, Cl, Br, I, CN, NO2,
-NRfRf, -C(O)Rf -C(O)ORf, -NRfC(0)Rf, -C(O)NRfRf -SO2NRfRf -NRfSO2NRfRf -NRfSO2-Ci_4 alkyl, -NRfSO2CF3, -NRfSO2-phenyl, -S(O)2CF3, -S(0)P-CM alkyl, -S(O)p-phenyl, -(CF2)rCF3, C).6 alkyl, C2-6 alkenyl, or C2.6 alkynyl;
R*1 is, independently at each occurrence, C]_g alkyl substituted with 0-2 RS, -(CH2)trphenyl substituted with 0-2 RS, or -(CH2)n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(0)p, wherein said heterocycle is substituted with 0-2 R8;
R" is, independently at each occurrence, H, C]_$ alkyl substituted with 0-2 R§. -(CH2)n-phenyl substituted with 0-2 RS, or -(CH2)n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(O)p, wherein said heterocycle is substituted with 0-2 RS; n, at each occurrence, is selected from 0, 1, 2, 3, and 4; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, and 4; s, at each occurrence, is selected from 0, 1, 2, and 3; and t, at each occurrence, is selected from 1, 2, 3, and 4; provided that when ring D is dihydroindolyl, ring A is other than thiazolyl.
2. A compound according to Claim 1, wherein: W is O; and X2 is a bond, -CH2-, -CH2CH2-, -CH2CHMe-, -CH2CO-, or
Figure imgf000008_0001
ompound according to Claim 1, wherein: ring B is substituted with 0-3 K7 and selected from:
Figure imgf000009_0001
ring D is substituted with 0-5 R6a and selected from:
Figure imgf000010_0001
wherein D1 is selected from: cyclopentyl, cylohexyl, piperidiii}4, tetrahydropyi"aiiyl, phenyl, pyridinyl, pyrimidinyl, thiophenyl, pyrrolyl, fuxanyl and thiazolyl;
W is O; and
X2 is a bond.
4. A compound according to Claim 1, wherein: ring A is substituted with 0-5 R1 and selected from: phenyl, pyridinyl, pyrimidinyl, furanyl, isoxazolyl, thiazolyl, thiadiazqlyl, benzothiazolyl, indolyl, and benziniidazolyl.
5. A compound according to Claim 1, wherein: ring A is substituted with 0-4 R1 and selected from: phenyl, pyridyl, isoxazolyl, furanyl, thienyl, thiazolyl, and benzothiazolyl; and ring B is substituted wititi 0-3 R7 and selected from:
Figure imgf000011_0001
6. A compound according to Claim 1, wherein: R1 is, independently at each occurrence, F, Cl, Br, I, CF3, -CF2CF3, OCF3,
-OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)rORc, SRC, CN5 NO2, -(CRfRf)rNR12R13, -(CRfRf)rC(O)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)r-C(O)NR12R13, -OP(O)(OEt)2, 4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl, C1 _g alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2-S alkynyl substituted with 0-2 Ra, -(CRfRf)1-C3.13 carbocycle substituted with 0-5 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR* 1, O, and S(O)p, wherein said heterocycle is substituted with 0-5 Rb; alternatively, two R1S on two adjacent carbon atoms are combined with the carbon atoms to which they attached, form a 5- to 7-membered carbocycle or • heterocycle comprising: carbon atoms and 0-3 additional heteroatoms selected from N, NR11 J O, and S(O)p, and 0-2 carbonyl groups, wherein said carbocycle or heterocycle is substituted with 0-4 Rb.
7. A compound according to Claim 1, wherein:
180 005/016525
R6a is, independently at each occurrence, F5 Cl, Br, I, -(CRiRVOR0, SRC, CN, CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -NR12R13, -C(O)Rc, -(CRfRf)rC(O)ORc, -Si(Me)3, CM haloalkyl, C] -4 haloalkyloxy-, C 1-4 alkyloxy-, CM alkylthio-, Ci-C4 alkyl-C(O)-, Cμ alkyl-O-C(O)-, CM alkyl-C(O)NH-, C1-8 alkyl substituted with 0-2 Ra 5 C2-8 alkenyl substituted with 0-2 Ra, C2-8 alkynyl substituted with 0-2 Ra, -(CRfRf)r-C3-1o carbocycle substituted with 0-2 Re, or -(CRfRf)1-S- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re; and alternatively, when two R^a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR1 ' , O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R6a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 ] , O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb.
8. A compound according to Claim 1, wherein:
R11 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2 Ra 5 -C(O)(CH2)n(C3.6 cycloalkyl), -C(O)(CH2)πphenyl, -C(O)O(C1-8 alkyl),
-C(O)O(CH2)n(C3.6 cycloalkyl), -C(O)O(CH2)nphenyl, -C(O)O(CH2)2-4(Ci-4 alkyl), -C(O)NH(CL6 alkyl), -S(O)2(C1-6 alkyl), -S(O)2(CH2)πphenyl, -(CRfRf)1-C3-7 cycloalkyl, -(CRfRf)r-phenyl, or -(CRfRf)1-S- to 6-membered heterocycle; wherein said alkyl, cycloaUcyl, phenyl, and aryl are substituted with 0-2 Rb, and said heteroaryl
181 and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NR/, O, and S(O)p.
9. A compound according to Claim 1, wherein: ring A is substituted with 0-4 Rl and selected from: phenyl, pyridyl, isoxazolyl, fαranyl, thienyl, thiazolyl, and benzothiazolyl; ring B is substited with 0-3 R7 and selected from:
Figure imgf000013_0001
ring D is substituted with 0-5 R^a and selected from:
182
Figure imgf000014_0001
wherein D1 is selected from: cyclopentyl, cyiohexyl, piperidinyl, tetrahydropyranyl, phenyl, pyridinyl, pyrimidinyl, thiophenyl, pyrrolyl, furanyl and thiazolyl;
W is 0;
X2 is a bond; R1 is, independently at each occurrence, F, Cl, Br, I5 CF3, -CF2 CF3, OCF3,
-OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)rORc, SRC, CN, NO2, -(CRfRf)rNR12R] 3, -(CRfRf)r-C(0)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)r-C(O)NR12R13, -OP(O)(OEt)2, 4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl, Cμ8 alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2_s alkynyl substituted with 0-2 Ra, -(CRfRf)rC3.i3 carbocycle substituted with 0-5 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N5 NR1 ', O5 and S(O)p, wherein said heterocycle is substituted with 0-5 BP; alternatively, two R1S on two adjacent carbon atoms are combined with the carbon atoms to which they attached, form a 5- to 7-membered carbocycle or heterocycle comprising: carbon atoms and 0-3 additional heteroatoms selected from N, NR1 1, O, and S(O)p, and 0-2 carbonyl groups, wherein said carbocycle or heterocycle is substituted with 0-4 Rb;
183 R6a is, independently at each occurrence, F, Cl, Br, I, -(CRiROrOR0, SRC, CN, CF3, OCF3, -CF2CF3, -OCF2CF2H5 -OCF2CF3, -NR12R13, -C(O)RC, -(CRfRf)rC(0)0Rc, -Si(Me)3, CM haloalkyl, C M haloalkyloxy-, C 1-4 alkyloxy-, C1.4 alkylthio-, Ci-C4 alkyl-C(O)-, CM alkyl-O-C(O)-, CM alkyl-C(O)NH-, C1-8 alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2-8 alkynyl substituted with 0-2 Ra, -(CRfRf)rC3-io carbocycle substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatorns selected from N, NR1 ' , O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re; alternatively, when two R6a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR1 3 , O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R6a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 1 J O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; and
R11 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2 Ra, -C(θχCH2)n(C3-6 cycloalkyl), -C(O)(CH2)nphenyl, -C(O)O(CL8 alkyl), -C(O)O(CH2)n(C3-6 cycloalkyl), -C(O)O(CH2)nphenyl, -C(O)O(CH2)2^(CM alkyl), -C(O)NH(Ci^ alkyl), -S(O)2(CL6 alkyl), -S(O)2(CH2)nphenyl5 -(CRfRf)rC3-7 cycloalkyl, -(CRfRf)rphenyl, or -(CRfRf)1-S- to 6-membered heteroc3'cle; wherein said alkyl, cycloalkyl, phenyl, and aryl are substituted with 0-2 Rb, and said heteroaryl and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(O)p.
184 10. A compound according to claim 1, wherein the compound is of Formula (Ia):
Figure imgf000016_0001
(Ia) or a stereoisomer or pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is
Figure imgf000016_0002
ring B is substituted with 0-3 R7 and selected from:
185
Figure imgf000017_0001
ring D is substituted with 0-5 R6a and selected from:
Figure imgf000017_0002
R1, Rla, R]b, and Rlc are, independently at each occurrence, H, F, Cl, Me, NH2, or OH;
R2, R2a, R2b, R2c5 R2d R35 R3a R3Cj R3d5 R4s R4a5 R4Cj R5? R5a? R5Cj ^d R5d are, independently at each occurrence, H, F, Cl, Br, I, CF3, -CF2CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)r-ORc, SRC, CN, NO2, -(CRfRf)1-NR^RlS5
186 -(CRfRf)u-C(O)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)11-C(O)NR12R13, -OP(O)(OEt)2, 4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl, C1-8 alkyl substituted with 0-2 Ra, -(CRfRf)u-C3-6 carbocycle substituted with 0-2 Rb, or -(CRfRf)u-5- to 6-membered lieterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Rb; alternatively, Rl + R2, R2 + R3, R3 + R4, R4 + R5, Rla + R2a, R2a + R3a, R3a + R4a R4a + R5a Rlb + R2bs R2b + R5d Rl c + R3c5 R2c + R3c? R2d + R3d
R3c + R4c; or R4c + R5c; combine with the carbon atoms to which they are attached, form 5- tolO-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR1 *, O, and S(O)p, 0-1 carbonyl group, and additional 0-2 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
R6a is, independently at each occurrence, F, Cl, Br, I, -(CRfRf)r-ORc, SRC, CN5 CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -NRl2R13, -C(O)RC, -(CRfRf)1-C(O)OR0, -Si(Me)3, Ci_4 haloalkyl, Ci_4 haloalkyloxy-, C1-4 alkyloxy-, CM alkylthio-, C1-C4 alkyl-C(O)-, C].4 alkyl-O-C(O)-, Ci_4 alkyl-C(O)NH-, Cμg alkyl substituted with 0-2 Ra, C2_8 alkenyl substituted with 0-2 Ra C2.g alkynyl substituted with 0-2 Ra, -(CRfRf)r-C3.io carbocycle substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRl 1, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re; alternatively, when two R^a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR11, O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R^a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocj'clic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N,
187 NR1 1, O, Si, and S(0)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb;
R7 is, independently at each occurrence, H, =0, F, Cl, Br, I, OCF3, CF3, ORC, SRc, CN, NO2, -NR12R13, -C(O)RC, -C(O)ORC, -C(O)NR12R13, -NR14C(0)Rd, -S(O)PNR12R13 , -S(O)Rd, -S(O)2Rd, C1-6 alkyl substituted with 0-2 Ra,
-(CH2)u-C3-io carbocycle substituted with 0-3 Rb, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR7b, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Rb;
R7b is H, C1-4 alkyl, -C(O)(Ci_4 alkyl), -C(O)phenyl, -C(O)benzyl, or benzyl; R11 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2
Ra, -C(O)(CH2)n(C3-6 cycloalkyl), -C(O)(CH2)πphenyl, -C(O)O(CL8 alkyl), -C(O)O(CH2)n(C3-6 cycloalkyl), -C(O)O(CH2)nphenyl, -C(O)O(CH2)2-4(Ci-4 alkyl), -C(O)NH(C1-6 alkyl), -S(O)2(Ci^ alkyl), -S(O)2(CH2)nphenyl, -(CRfRf)r-C3_7 cycloalkyL -(CRfRf)rphenyl, or -(CRfRf)r-5- to 6-membered heterocycle; wherein said alkyl, cycloalkyl, phenyl, and aryl are substituted with 0-2 Rb, and said heteroaryl and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p;
R12 is, independently at each occurrence, H, C 1-6 alkyl, -C(O)(C1-6 alkyl), -C(O)(CH2)nphenyl, -C(O)(CH2)n(5- to 6-membered heteroaryl), -C(O)O(C1-4 alkyl), -C(O)OCH2phenyl, -(CH2)nC(O)OCH2(5- to 6-membered heteroaryl), -(CH2)X1OC(O)(C1-4 alkyl), -(CH2)nOC(O)phenyl, -(CH2)nOC(O)(5- to 6-membered heteroaryl), -(CH2)nC(O)O(C1-4 alkyl), -(CH2)nC(O)Ophenyl, -(CH2)nC(O)O(5- to 6-membered heteroaryl), -(CH2)πC(O)NH(d.6 alkyl), -(CH2)nC(O)NHphenyL -(CH2)πC(O)NH(5- to 6-membered heteroaryl), -(CH2)tOC(O)NH(Ci-6 alkyl), -(CH2)tOC(O)NHphenyl, -(CH2)tOC(O)NH(5- to 6-membered heteroaryl), -S(O)2(C1-6 alkyl), -S(O)2(CH2)nphenyl, -S(O)2(CH2)n(5- to 6-membered heteroaryl),
Figure imgf000019_0001
or -(CRfRf)n- 5- to 6-membered heteroaryl; wherein said alkyl, and arjd are substituted with 0-2 RS; and said heteroaryl is substituted with 0-2 Rg and comprises: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p;
R13 is, independently at each occurrence, H, Cμg alkyl, or -(CH2)n-phen}4; alternatively, R12 and R13, when attached to the same nitrogen, combine to form a 5- to 10-membered heterocyclic ring comprising: carbon atoms and 1-2 additional heteroatoms selected from N, NR11, O, and S(O)p;
R14 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2 R14a, C2_6 alkenyl substituted with 0-2 R14a, Ci-β alkynyl substituted with 0-2 R14a, -(CH2)U-C3_6 cycloalkyl substituted with 0-3 RS, -(CH2)u-phenyl substituted with 0-3 Rg, or -(CH2)u-5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Rg;
R14a is, independently at each occurrence, H, C1-4 alkyl, ORf, Cl, F, Br, I, =0, CF3, CN5 NO2, -C(O)Rf, -C(O)ORf -C(O)NR12R13, or -S(O)pRf; Ra is, independently at each occurrence, H3 =0, F, OCF3, CF3, ORC, SRC, CN,
-NR12R13, -C(O)RC, -C(O)ORC, -C(O)NR12R13, -NR14C(0)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, -(CH2)u-C3_io carbocycie substituted with 0-3 Re, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
Rb is, independently at each occurrence, H, =0, F, Cl, Br, I, -(CH2)r-ORc, SRC, CN, NO2, CF3, OCF3, -(CH2)r-NR12R13, -C(O)R0, -(CH2)rC(O)ORc, -(CH2VC(O)NR12R13, -NR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd Ci-4 haloalkyl, Ci_4 haloalkyloxy-, C1-4 alkyloxy-, Cχ_4 alkylthio-, Ci_4 alkyl-C(O)-, C 1.4 alkyl-O-C(O)-, C j .4 alkyl-C(O)NH-, C1-6 alkyl substituted with 0-2 Ra, C2-4 alkenyl substituted with 0-2 Ra, C2-4 alkynyl substituted with 0-2 Ra, -(CH2)u-C3_io carbocycie substituted with 0-3 Re, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
189 Rc is, independently at each occurrence, H, -0P(0)(0Et)2, Ci_8 alkyl substituted λvith 0-2 Re, C2-4 alkenyl substituted with 0-2 Re, C2-4 alkynyl substituted with 0-2 Re, -(CH2)u-C3-8 cycloalkyl substituted with 0-2 Re, -(CH2)u-C6-io ^Y1 substituted with 0-2 Re, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon, atoms and 1-4 heteroatorns selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Rd is, independently at each occurrence, CF3, OH5 C] .4 alkoxy, Cj.6 alkyl, -(CH2)u-C3-io carbocycle substituted with 0-2 Re, or -(CH2)u-5- to 10- membered heterocycle comprising: carbon atoms and 1-4 heteroatorns selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Re is, independently at each occurrence, H, =0, -(CH2)r-0Rf, F, Cl, Br, I, CN, NO2, -(CH2)U-NR12R13, -C(O)Rf -(CH2)r-C(O)ORf, -NR14C(0)Rf, -(CH2VC(O)NR12RlS5 -SO2NRl2Rl3, -NRl4SO2NR12Rl3, -NRWSO2-C1-4 alkyl, -NRl4SO2CF3, -NR14SO2-ρhenyl, -S(O)2CF3, -S(O)p-Cμ4 alkyl, -S(O)p-phenyl, ~(CF2)UCF3, Ci_6 alkyl substituted with 0-2 RS, C2_4 alkenyl substituted with 0-2 Rg, C2-4 alkynyl substituted with 0-2 RS5 -(CH2)U-C3-S cycloalkyl substituted with 0-2 RS, -(CH2VC6-10 aryl substituted with 0-2 RS, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatorns selected from N, NRf, O, and S(O)p, Λvherein said heterocycle is substituted with 0-2 RS; Rf is, independently at each occurrence, H, or Cj-4 alkyl;
RS is, independently at each occurrence, H, =0, ORf, F, Cl, Br, I, CN, NO2, -NRfRf -C(O)Rf -C(O)ORf -NRfC(O)Rf, -C(O)NRfRf -SO2NRfRf, -NRfSO2NRfRf 5 -NRfSO2-Ci_4 alkyl, -NRfSO2CF3, -NRfSO2-phenyl, -S(O)2CF3, -S(0)p-Ci-4 alkyl, -S(O)p-phenyl, -(CF2)uCF3, Cχ_6 alkyl, C2-4 alkenyl, or C2.4 alkynyl; Rh is, independently at each occurrence, C^g alkyl substituted with 0-2 Rg, or
-(CH2)n-phenyl substituted with 0-2 Rg; n, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from O5 I5 and 2; r5 at each occurrence, is selected from O5 1, 2, 35 and 4;
190 s, at each occurrence, is selected from O, 1, 2, and 3; t, at each occurrence, is selected from 1 and 2; and u, at each occurrence, is selected from O, 1, and 2; provided that when ring D is dihydroindolyl, ring A is other than thiazolyl.
11. A compound according to claim 1, wherein the compound is of Formula (Ia):
Figure imgf000022_0001
(Ia) or a stereoisomer or pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is
Figure imgf000022_0002
ring B is
191
Figure imgf000023_0001
ring D is selected from:
Figure imgf000023_0002
192
Figure imgf000024_0001
wherein the phenyl ring in each of the structures is substituted with 0-2 R6a;
R1, Rla, and Rlb ai-e, independently at each occurrence, H, F, Cl, Me, NH2,
OH,
Figure imgf000024_0002
or phenoxy substituted with 0-2 Re;
. R2, R2b, R2c, and R2d are, independently at each occurrence, H, F, Cl, Br,
193 Ci-6 alkyl, Ci_6 aUcoxy, -O(CH2)8CO2Me, -O(CH2)2C(Me)2θMe3 -O(CH2)2OCOMe, NO2, CF3, CF2CF3, 2-CH2N(Me)2-Ph, Ph, cyclohexoxy, 4-Me-cyclohexoxy, cyclohexyhnethoxy, (1 -Bn-pyrrolidin-3-3'l)oxy, (1 -Bn-pyrrolidin-3-yl)methoxy, (1 H-pyrrol-1 -yl)ethoxy, (2-Bu-l H-irαidazol-4-yl)methoxy, (1 -Ph- IH-1, 2,3 -triazol-4-yl)methoxy, l-Bn-piperidin-3-oxy, l-Bn-piperidin-4-oxy, 4-Bn-morpholiii-2-yl-methoxy, benzoxy, 4-CO2Me-benzoxy or SiMe3;
R3, R3a 5 R3c, and R3d are, independently at each occurrence, H, F, Cl, Br, Ci_6 alkyl, Ci_6 alkoxy, -OCH(Me)CH2O-^-Bu, CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, NH2, NMe2, -CH2NMe2, NEt2, -NHPh, -N(Me)Ph, -NH(4-0Me-Ph), -NH(2-CF3-Ph), -NH(2-f-Bu-Ph), -CH(Me)N(Me)(3-CF3-Bn), -CH(Me)N(Me)(4-CF3-Bn), -CH(Me)N(Me)(furan-2-ylmethyl),
-CH(Me)N(Me)(tliien-2-ylmethyl), -CH(Me)NHCH(Me)Ph, -CH(Me)OH, -CH(Me)O(Z-Pr)5 -CH(Me)O(Z-Bu), -CH(Me)O(3-CF3-Bn), -CH(Me)O(4-CF3-Bn),
-CH(Me)O(l-Bn-pyrrolidm-3-ylmethyl), -CH(Me)OCH2C(Me)2CH2NMe2, -CH(Me)OBn, -CH(Me)0(4-z-Pr-Bn), -CH(Me)0(4-0Ph-Bn),
-CH(Me)O(3,5-diCl-Bn), -CH(Me)OCH2(l-Bn-piperidin-4-yl), -CH2NHBn, -CH2NH(4-CF3-Bn), -CH2N(Me)Bn, -CH(Me)NHCH2-pyridin-2-yl, -CH(Me)NHCH2-p>τidin-4-yl, -CH(Me)NHCH2(6-Cl-pyridin-3-yl), -CH(Me)N(Me)(Z-Bu), -CH(Me)N(Me)Bn, -CH(Me)N(Me)(4-0Me-Bn), -CH(Me)N(Me)(4-F-Bn), -CH(Me)N(Me)(3-Cl-Bn), -CH(Me)N(Me)(4-Cl-Bn), -CH(Me)N(Me)(3,4-diCl-Bn), -CH(Me)N(Me)CH2CH2Ph, -CH(Me)N(Me)CH2-pyridin-2-yl, -CH(Me)N(Me)CH2-pyridin-3-yl, -CH(Me)N(Me)CH2-pyridin-4-yl, -CH(Me)N(Me)CH2-fui-an-2-yl, -CH(Me)N(Me)CH2-thien-2-yl, -CH(Me)N(Me)CH2-(5-Me-thien-2-yl), -CH(Me)N(Me)CH2-(5-Cl-thien-2-yl), -CH(Me)N(Et)Bn, -CH(Me)N(Et)(4-Me-Bn), -CH(Me)N(Et)(2-Cl-Bn), -CH(Me)N(Bn)CH2CN, -CH(Me)N(Bn)CH2CH2OH, -CH(Me)N(Bn)CH2CO2Me5 -CH(Me)N(Bn)CH2CONMe2, -CH(Me)N(Bn)CH2CON(Me)(Bn), -CH(Me)-isoindolin-2-yl, -CH(Me)-(1 ,2,3, 4-tetrah3^droisoquinolin-2-yl), -CH(Me)(4-Bn-piρerazin-l -yl), COMe, CO2Me, CO2Et, -CH2CO2Me5 -C(Me)2CO2Me, -O(CH2)5CO2Et5
194 -0(CH2)SCO2Me, -O(CH2)2C(Me)2OMe, -O(CH2)2OCOMe, -OCH2C(Me)2CH2NMe2, Ph, 2-CH2OH-Ph, 2-CH2N(Me)2-Ph, 3-CH2N(Me)2-Ph, 4-CH2N(Me)2-Ph, 2-((3-OH-pyrrolidin-l-yl)methyl)-Ph, phenoxy, 2-f-Bu-phenoxy, 2-CF3-phenoxy, Bn, benzoxy, 3-OMe-benzoxy, 4-CO2Me-benzoxy, 4-OCF3 -benzoxy, 2,4-diF-benzoxy, cyclohexyknethoxy, cyclohexylethoxy, cyclopentoxy, 3-Me-cycIopentoxy, cyclohexoxy, 4-Me-cyclohexoxy, 4-CO2Et-cyclohexoxy, l-Bn-pyrrolidin-3-oxy, (l-Bn-pyrrolidin-3-yl)methoxy, 1 H-pyrazol- 1 -yl, 3-CO2Et-5-Me- 1 H-pyrazol- 1 -yl, 4-CO2Et-5-Me- 1 H-pyrazol- 1 -yl, 5-Cθ2Et-3-Me-lH-ρyrazol-l-yl, (2-Bu-lH-iraidazol-4-yl)methoxy, lH-l,2,4-triazol-l-yl, (l-Ph-lHrl,2,3-triazol-4-yl)methoxy, 2-(lH-pyrrol-l-yl)ethoxy5 1 -piperidinyl, 1 -Bn-piperazin-4-yl, (2,2-diinethyl- 1 ,3-dioxolan~4-yl)methoxy, 1 -Bn-piperidin-3-oxy, 1 -Bn-piperidin-4-oxy, ( 1 -(z-Bu)-piperidin-4-yl)methoxy, (1 -isopentyl-piperidin-4-yl)methoxy, (1 -CO2(^-Bu)-piperidin-4-yl)methoxy, (1 -CO2Bn-piperidin-4-yl)methoxy, (1 -Bn-piperidin-4-yl)methoxy, (1 -phenethyl-piperidui-4-yl)methoxy, (1 -(4-phenylbutyl)~pipεridin-4-yl)methoxy, ( 1 -cyclohexylmetliyl-piperidin-4-yl-methoxy, (l-((pyridin-2-yl)methyl)-piperidin-4-yl)metlioxy, ( 1 -((pyridin-4-yl)metliyl)-piperidin-4-yl)methoxy, (1 -((153-dioxolan-2-yl)methyl)piperidin-4-yl)methoxy, N-morpholinyl, 4-Bn-morpholin-2-yl-methoxyJ C3-6 cycloalkyl substituted with -CO2Me, -CH2OH5 or -CH2OMe, 4,4,5,5-tetramethyl-l,3,2-dioxaboiOlanyl, or -OP(O)(OEt)2;
R4, R4a, aiαd R4c are H;
R5, R5a, R5c, and R5d are, independently at each occurrence, H, Me, F or Cl; alternatively, R1 + R2, R2 + R3, R3 + R4, R4 + R5, R3a + R4a, R4a + R5a,
Rib + R2b5 R2c + R3c5 R3c + R4c5 R4c + R5c} Rlb + R2b; R2d + R3d? or R2b + R5d; combine with the carbon atoms to which they attached, form 5- tolO-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR11, O, and S(0)p, 0-1 carbonyl group, and additional 0-2 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
R6a is, independently at each occurrence, H, F, Cl, Br, I, CN, -C(Me)2CN,
195 C i_8 alkyl, C2-8 alkenyl, OH, SMe, S(Z-Pr), -C(Me)2OMe, -C(Me)2OEt, -C(Me)2OPr, -CHMeO(CH2)2OMe, -C(Me)2O(CH2)2OMe, -C(Et)2OMe, -C(Et)2OEt, COPh, -CH=CHCO2(^-Bu), CF3, OCF3, Ci-4 alkyloxy, CO2Me, -CH2CO2Me, C3_7 cycloalkyl, Ph, Bn, 1-pyrrolidinyl, 5-isoxazolyl, N-morpholinyl, 4-Bn-piperazinyl, 1-piperidinyl, l-Bn-piperidin-4-yl, Or -Si(Me)3; alternatively, when two R6a groups are attached to the same carbon atom, together with the carbon atom to which they are attached, they form a 3- to 7- membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 ], O, and S(0)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb; alternatively, when two R^a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR11, O, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
R7, R7a R7b, and R7d, independently at each occurrence, H, Me, Cl, Br, CN, OMe, SMe, or NHMe;
R8, R8a , R8b and R8e are, independently at each occurrence, H, Me, Cl, or CN;
R11 is, independently at each occurrence, Cμg alkyl, -CH2CH2OH, -CH2CH2OMe, -C(O)(C] -6 alkyl), -C(O)phenyl, -C(O)benzyl, -C(O)O(Ci-6 alkyl), -C(O)Obenzyl, -CH2CO2H, -CH2CO2(Ci-6 alkyl), -C(O)NH(Ci-6 alkyl), -C(O)NHbenzyl, -S(O)2(Ci_6 alkyl), -S(O)2phenyl, -S(O)2benzyl, phenyl, or benzyl;
Y is O, S, or NH;
Rb is, independently at each occurrence, H, F, Cl, Br, C] .4 alkyl, OH, CO2H, NH2, CF3, OCF3, Ci-4 alkyloxy, C3_7 cycloalkyl, phenyl, or benzyl;
Re is, independently at each occurrence, H, F, Cl, Cj .4 alkyl, OH, CO2H, NH2, CF3, OCF3, or CM alkyloxy; and p, at each occurrence, is selected from 0, 1, and 2; provided that when ring D is dihydroindolyl, ring A is other than thiazolyl.
196
PCT/US2005/016525 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions Ceased WO2005113537A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL05779448T PL1750704T3 (en) 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
MXPA06013024A MXPA06013024A (en) 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions.
DK05779448T DK1750704T3 (en) 2004-05-12 2005-05-11 Urea Antagonists of P2Y1 Receptors Useful in the Treatment of Thrombotic Conditions
JP2007513323A JP4795336B2 (en) 2004-05-12 2005-05-11 P2Y1 receptor urea antagonist useful for the treatment of thrombotic conditions
DE602005015577T DE602005015577D1 (en) 2004-05-12 2005-05-11 UML ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES
CN2005800231306A CN1984655B (en) 2004-05-12 2005-05-11 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP05779448A EP1750704B1 (en) 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
HR20090468T HRP20090468T1 (en) 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
CNA2005800236206A CN1984892A (en) 2004-05-12 2005-05-11 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AU2005245400A AU2005245400A1 (en) 2004-05-12 2005-05-11 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
NO20065544A NO20065544L (en) 2004-05-12 2006-12-01 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions.
CY20091101048T CY1109487T1 (en) 2004-05-12 2009-10-13 P2Y1 RECEPTOR UREA-TYPE ANTAGONISTS USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57028804P 2004-05-12 2004-05-12
US60/570,288 2004-05-12
US66573505P 2005-03-28 2005-03-28
US60/665,735 2005-03-28
US11/126,567 2005-05-10
US11/126,567 US7550499B2 (en) 2004-05-12 2005-05-10 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Publications (3)

Publication Number Publication Date
WO2005113537A2 WO2005113537A2 (en) 2005-12-01
WO2005113537A3 WO2005113537A3 (en) 2005-12-22
WO2005113537B1 true WO2005113537B1 (en) 2006-02-16

Family

ID=35169638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016525 Ceased WO2005113537A2 (en) 2004-05-12 2005-05-11 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions

Country Status (17)

Country Link
US (1) US7550499B2 (en)
EP (1) EP1750704B1 (en)
JP (1) JP4795336B2 (en)
KR (1) KR20070011479A (en)
CN (2) CN1984892A (en)
AU (1) AU2005245400A1 (en)
CY (1) CY1109487T1 (en)
DE (1) DE602005015577D1 (en)
DK (1) DK1750704T3 (en)
ES (1) ES2328716T3 (en)
HR (1) HRP20090468T1 (en)
MX (1) MXPA06013024A (en)
NO (1) NO20065544L (en)
PL (1) PL1750704T3 (en)
PT (1) PT1750704E (en)
SI (1) SI1750704T1 (en)
WO (1) WO2005113537A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
AU2005245389A1 (en) 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
DE602006021306D1 (en) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
ATE485269T1 (en) * 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC DISORDERS
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2008023235A1 (en) * 2006-08-25 2008-02-28 Pfizer Products Inc. Pyrazole derivatives as anti-platelet and anti-thrombotic agents
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR100858460B1 (en) * 2007-05-16 2008-09-12 최원진 Preparation of Pickles
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
NZ601788A (en) * 2010-03-01 2014-11-28 Myrexis Inc Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof
EA201490152A1 (en) 2011-06-24 2014-05-30 Эмджен Инк. TRPM8 ANTAGONISTS AND THEIR APPLICATION IN TREATMENT
JP2014517074A (en) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド TRPM8 antagonists and their use in therapy
WO2013017678A1 (en) 2011-08-04 2013-02-07 Intervet International B.V. Novel spiroindoline compounds
CN103172543B (en) * 2011-12-21 2016-02-10 中国科学院上海药物研究所 A kind of carbamide compounds, preparation method and its usage
WO2014022349A1 (en) * 2012-08-01 2014-02-06 Bristol-Myers Squibb Company 7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor
WO2014022343A1 (en) * 2012-08-01 2014-02-06 Bristol-Myers Squibb Company 7-hydroxy-indolinyl antagonists of p2y1 receptor
EP2880034B1 (en) 2012-08-01 2016-06-22 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
CN102924442B (en) * 2012-11-15 2014-10-29 沈阳药科大学 Chroman compound containing thiazole ring and analogue and medical applications thereof
CN103012381B (en) * 2013-01-10 2015-01-07 山东大学 Benzofuran compound, preparation method thereof and application of benzofuran compound in preparation of antiarrhythmic drugs
CN104402875A (en) * 2014-12-25 2015-03-11 西安山川医药科技有限公司 Synthesis method and application N-(2-aminoethyl)-N'-(6-substituted-2-benzothiazolyl)urea and salt compounds thereof
GB201721957D0 (en) * 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721964D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721960D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721961D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721967D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
CN110305141B (en) * 2019-07-18 2022-01-11 深圳市三启药物开发有限公司 Spiro (3, 3' -isopropyl pyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof
CN114853684A (en) * 2021-02-03 2022-08-05 北京万全德众医药生物技术有限公司 Purification method of Lomepilon intermediate
EP4095134A1 (en) 2021-05-25 2022-11-30 UCL Business Ltd Polycyclic compounds for the treatment of neurological indications
EP4094762A1 (en) 2021-05-25 2022-11-30 UCL Business Ltd Treatment of neurological indications

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3118888A (en) 1964-01-21 Acylated s-triazines and process for their preparation
NL280954A (en) 1961-07-14
US4179563A (en) 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
US4186199A (en) 1978-11-02 1980-01-29 American Hoechst Corporation Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
JPS56166180A (en) 1980-05-28 1981-12-21 Chugai Pharmaceut Co Ltd Dibenzoxazepine derivative and its preparation
JPS56167649A (en) 1980-05-30 1981-12-23 Chugai Pharmaceut Co Ltd Diphenyl ether derivative
JPS5872562A (en) * 1981-10-23 1983-04-30 Mitsubishi Chem Ind Ltd Tetrahydrophtahlimides
US4663453A (en) 1983-05-18 1987-05-05 Hoechst-Roussel Pharmaceuticals Inc. Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
US4761411A (en) 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
JPS62280847A (en) 1986-05-30 1987-12-05 Konica Corp Silver halide photographic sensitive material containing new magnenta coupler
US4840947A (en) 1986-10-14 1989-06-20 Hoechst-Roussel Pharmaceuticals, Inc. Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas
JP2577222B2 (en) 1987-04-10 1997-01-29 興和株式会社 New substituted anilide derivatives
JPH0339740A (en) 1989-07-06 1991-02-20 Konica Corp Transfer type heatdevelopable color photosensitive material
JP2951434B2 (en) 1991-04-18 1999-09-20 三菱製紙株式会社 Electrophotographic photoreceptor
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
JP3395285B2 (en) 1993-10-06 2003-04-07 日本製紙株式会社 Thermal recording medium
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE4443641A1 (en) 1994-12-08 1996-06-13 Bayer Ag Substituted carboxamides
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 receptor antagonists
PL322843A1 (en) 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
AU7340096A (en) 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
CZ298098A3 (en) 1996-03-25 1999-02-17 Eli Lilly And Company Tetrahydro-beta-carbolic compounds
CA2241687A1 (en) 1996-10-30 1998-05-07 Kenneth A. Jacobson P2y receptor antagonists
US6020357A (en) 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5858289A (en) 1997-02-24 1999-01-12 Global Consulting, Inc. Process for preparing compressed shape of ceramic fiber
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
AR016817A1 (en) * 1997-08-14 2001-08-01 Smithkline Beecham Plc DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
RU2212407C2 (en) 1997-11-10 2003-09-20 Бристол-Маерс Сквибб Компани Benzothiazole inhibitors of protein tyrosine kinases
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DK1042305T3 (en) 1997-12-22 2005-09-19 Bayer Pharmaceuticals Corp Inhibition of p38 kinase using symmetric and asymmetric diphenylureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
CA2318199A1 (en) * 1998-01-15 1999-07-22 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
DK1094816T3 (en) 1998-07-06 2009-04-06 Bristol Myers Squibb Co Biphenylsulfonamides as dual angiotensin endothelin receptor antagonists
ATE287875T1 (en) 1998-10-06 2005-02-15 Dainippon Pharmaceutical Co 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, ACTIVE INGREDIENT PREPARATIONS CONTAINING THEM AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION
ATE290524T1 (en) 1998-10-20 2005-03-15 Takeda Pharmaceutical AROMATIC AMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MATERIALS CONTAINING SAME
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
HUP0202248A3 (en) 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
HUP0202708A3 (en) 1999-04-15 2004-12-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
CO5200760A1 (en) 1999-06-16 2002-09-27 Smithkline Beecham Corp RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8
JP2001089412A (en) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd Benzene derivative or its pharmaceutically acceptable salt
WO2001023358A1 (en) 1999-09-27 2001-04-05 Sagami Chemical Research Center Pyrazole derivatives, intermediates for the preparation thereof, processes for the preparation of both and herbicides containing the derivatives as the active ingredient
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
ATE336492T1 (en) 2000-01-14 2006-09-15 Us Gov Health & Human Serv METHONOCARBACYCLOALKYLANALOGUES OF NUCLEOSIDES
WO2001055146A1 (en) 2000-01-29 2001-08-02 Lg Chem Investment Ltd. FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
DE60114994T2 (en) * 2000-02-04 2006-08-03 Portola Pharmaceuticals, Inc., South San Francisco PLATELET ADP RECEPTOR INHIBITORS
SK12712002A3 (en) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg 2-Benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2001074793A2 (en) 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
JP2004517936A (en) 2001-01-31 2004-06-17 ピーアンドジー−クレイロール・インコーポレイテッド A new coupler for use in oxidative hair dyeing
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
US6706711B2 (en) 2001-04-27 2004-03-16 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitor
IL158783A0 (en) 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
JP2005501873A (en) 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト Amine derivatives
WO2003013517A1 (en) 2001-08-06 2003-02-20 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors
CN102617567A (en) 2001-09-21 2012-08-01 百时美施贵宝公司 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
WO2003045920A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
US20050154230A1 (en) 2001-12-26 2005-07-14 Bayer Healthcare Ag Urea derivatives
JP2003192587A (en) 2001-12-26 2003-07-09 Bayer Ag Urea derivative
AU2003210969A1 (en) 2002-02-11 2003-09-04 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
DE10213228A1 (en) 2002-03-25 2003-10-16 Bayer Ag Cyclopentene derivatives
CN1665808A (en) 2002-05-06 2005-09-07 沃泰克斯药物股份有限公司 Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase
CA2488642C (en) 2002-06-27 2011-09-06 Dharma Rao Polisetti Aryl carbonyl derivatives as glucokinase activators
US20060058395A1 (en) 2002-08-01 2006-03-16 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
DE60328202D1 (en) 2002-09-05 2009-08-13 Neurosearch As DIARYL HARVEST DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
EP1565429B1 (en) 2002-11-21 2009-05-13 Neurosearch A/S Diaryl ureido derivatives and their medical use
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
WO2004085433A2 (en) 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
TWM252710U (en) 2003-07-18 2004-12-11 Huei-Chiun Shiu Annealing equipment
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co Diphenyl ether compound, process for producing the same, and use
AU2004266228A1 (en) 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonists
CA2541751A1 (en) 2003-10-14 2005-04-28 Eli Lilly And Company Phenoxyether derivatives as ppar modulators
PE20050444A1 (en) 2003-10-31 2005-08-09 Takeda Pharmaceutical PYRIDINE COMPOUNDS AS PEPTIDASE INHIBITORS
ES2711313T3 (en) 2003-12-26 2019-05-03 Masatoshi Hagiwara Method of regulating the phosphorylation of the SR protein and antiviral agents that comprise the regulator of the activity of the SR protein as an active ingredient
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
AU2005245389A1 (en) 2004-05-12 2005-12-01 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
CA2598993C (en) 2005-02-25 2013-09-03 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
DE602006021306D1 (en) 2005-06-27 2011-05-26 Bristol Myers Squibb Co
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE485269T1 (en) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC DISORDERS
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions

Similar Documents

Publication Publication Date Title
WO2005113537B1 (en) Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
RU2399620C2 (en) Quinuclidine derivatives and use thereof as m3 muscarinic receptor antagonists
ES2858314T3 (en) Procedure for antifungal compound
JP2002030084A5 (en)
WO2007002635B1 (en) C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
JP2002536329A5 (en)
JP2006524222A5 (en)
JP2009537461A5 (en)
JP2006505543A5 (en)
JP2005539088A5 (en)
JP2006504658A5 (en)
US8877787B2 (en) EP4 agonist
JP2005504042A5 (en)
WO2006078621B1 (en) 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
AU2015231234A1 (en) Antifungal compound process
JP2007520440A5 (en)
JP2003502367A5 (en)
JP2008545718A5 (en)
JP2003507380A5 (en)
JP2007538031A5 (en)
KR100785675B1 (en) Calcium receptor antagonist
JP2009503110A5 (en)
RU2000101307A (en) CHALKONS WITH ANTI-PROLIFERATIVE ACTIVITY
TWI555744B (en) Novel EP4 agonists
WO1997049388A1 (en) Remedies for renal diseases and organ-preserving agents